According a press release and a recent article from Drug Topics, AstraZeneca’s investigational vaccine candidate AZD12222 expanded into a phase 3 clinical trial.
The trial is funded by the Biomedical Advanced Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID).
Up to 30,000 adults aged 18 years or older will be enrolled to assess the safety and immunogenicity of AZD1222, which was co-invented by the University of Oxford and Vaccitech.
For more information, read the full article from Drug Topics.
Contemporary OB/GYN Senior Editor Angie DeRosa gets insight on the current state of COVID-19 from Christina Han, MD, division director of maternal-fetal medicine at the University of California, Los Angeles, and member of its COVID-19 task force. Han is an active member of the Society for Maternal-Fetal Medicine and discusses the issues on behalf of SMFM.
Listen
Surge of antidepressant use seen among female adolescents during COVID-19
March 7th 2024A study revealed a significant increase in antidepressant prescriptions among adolescents and young adults during the COVID-19 pandemic, particularly among female adolescents, indicating exacerbation of pre-existing mental health challenges.
Read More
COVID-19 vaccination during pregnancy not linked to preterm birth
January 31st 2024A systematic review of 6 studies revealed that COVID-19 vaccination during pregnancy does not significantly increase the risk of preterm birth, providing crucial insights for public health policies and offering reassurance to healthcare providers and expectant mothers.
Read More